Drug Sponsors

Astellas and Optimer collaborate on fidaxomicin in Japan

Monday, April 2, 2012 03:57 PM

San Diego-based Optimer Pharmaceuticals and Tokyo-based Astellas Pharma have formed an exclusive collaboration and license agreement to develop and commercialize fidaxomicin tablets in Japan for the treatment of Clostridium difficile infection (CDI) affecting the colon.

More... »

Compugen expands to California to develop mAb drug candidates

Monday, April 2, 2012 03:31 PM

Compugen Inc., a Canadian therapeutic product discovery company, has established new operations in South San Francisco, Calif., for the development of oncology and immunology monoclonal antibody (mAb) drug candidates against Compugen-discovered targets.

More... »

Hikma Pharma unveils $300 million expansion

Monday, April 2, 2012 02:33 PM

Hikma Pharmaceuticals, a generic drug and injectables specialist based in Amman, Jordan, plans to spend nearly $300 million in 2012 on acquisitions and expansion initiatives in the Middle East and North Africa, according to Hikma’s CFO, Khalid Nabilsi.

More... »

Teva Canada sells Quebec facility to Halo Pharmaceutical

Monday, April 2, 2012 11:01 AM

Teva Canada has finalized an agreement under which Halo Pharmaceutical, a contract manufacturing organization based in Whippany, N.J., will acquire Teva's manufacturing facility in Mirabel, Quebec.

More... »

Daiichi forms diabetes alliance with NGM Biopharma

Friday, March 30, 2012 03:07 PM

Tokyo-based Daiichi Sankyo has formed a partnership with San Francisco-based NGM Biopharmaceuticals to research and develop new treatments for diabetes.

More... »

Roche increases offer for Illumina $51 per share

Friday, March 30, 2012 09:17 AM

Roche has increased its offer price for all outstanding publicly-held shares of Illumina, $51 per share in cash. All other terms and conditions of the tender offer remain unchanged.

More... »

Bausch + Lomb acquires ISTA Pharmaceuticals

Wednesday, March 28, 2012 10:47 AM

Bausch + Lomb, the global eye health company, has signed a definitive agreement to buy ISTA Pharmaceuticals for $9.10 per share in cash, or an approximate total of $500 million. The transaction was unanimously approved by the boards of directors of both companies and is expected to close in the second quarter of 2012.

More... »

Celtic launches $50 million antibody drug conjugates company

Monday, March 26, 2012 12:19 PM

Celtic Therapeutics Management, a global private equity firm focused on novel therapeutic product candidates, has announced a significant commitment to Antibody-Drug-Conjugate (ADC) products with the launch of a new Lausanne, Switzerland-based company, ADC Therapeutics Sarl.

More... »

Valeant Pharmaceuticals to acquire Natur Produkt in Russia

Monday, March 26, 2012 10:58 AM

Valeant Pharmaceuticals International has signed a $180 million agreement to acquire Natur Produkt International, a specialty pharmaceutical company in St. Petersburg, Russia.

More... »

Bend Research launches biotherapeutics development initiative

Monday, March 26, 2012 10:52 AM

Bend Research, an independent drug-formulation development and manufacturing company based in Bend, Ore., has launched an initiative to expand its scientific and engineering expertise into biotherapeutics.

More... »